Adult-Onset ADHD Diagnosis and Stimulant Initiation with a Remote Adolescent Substance History
A new diagnosis in adulthood, and a genuine risk-stratification question rather than a reflexive prescribing decision: how a decades-old, resolved substance episode should actually weigh against an effective, otherwise-appropriate treatment.
For twenty-six years, W.H. built an entire identity around a story that turns out to have been only half true: that he was simply someone who couldn't sit still and didn't try hard enough, the kid every teacher's comment card called "bright but unfocused" without anyone ever suggesting there might be a reason for it. He is 41 now, watching his own son go through a school ADHD evaluation this fall, and it was his son's evaluator — not a doctor of his own — who first suggested, almost offhand, that W.H. himself might want to get assessed. He did. The diagnosis that came back named, at 41, something that had shaped every report card, every job he'd talked himself out of pursuing, and a marriage he privately credits his wife's patience for surviving.
The evaluation surfaced something else too, from further back: at 17 and 18, W.H. used cocaine recreationally for roughly a year, stopped on his own without treatment when a close friend overdosed, and has had no substance use of any kind — no alcohol beyond an occasional beer, no other drugs — in the twenty-three years since. He mentioned it only because the intake form asked directly, and he seemed almost surprised it was relevant at all; to him it belongs to a version of himself he stopped being before he'd finished being a teenager. The question in front of the team is genuinely different from a recent-relapse-risk calculation: how much should a single, resolved, decades-old substance episode weigh against a diagnosis whose most effective treatment is the same pharmacologic family.
A decades-old, resolved substance episode against a lifelong diagnosis
Twenty-three years of abstinence following a single, self-resolved adolescent episode is about as low-risk a substance history as exists in this population. Wilens and colleagues' meta-analytic work on stimulant treatment and later substance-use risk found that treated ADHD does not increase, and in several studies trends toward decreasing, subsequent SUD risk relative to untreated ADHD. Relapse risk in stimulant misuse correlates far more strongly with recency and severity than with the mere presence of any history at all — a distant, resolved episode with no subsequent pattern isn't the same risk category as active or recent use, and treating it as though it were would systematically undertreat every adult whose ADHD went unrecognized until well after an adolescent phase most people age out of.
I agree the risk category is genuinely different, but I'd still start conservatively rather than treat "low-risk" as "no different from a patient with no history at all." An extended-release stimulant, not immediate-release, and a standard rather than accelerated titration — not because I think he's likely to misuse it, but because starting cautiously costs him almost nothing given how effective this class typically is, and there's no clinical reason to skip that caution just because the risk is low rather than absent.
If his history included any use in the past several years, or any pattern beyond a single self-limited period, this would be a different, more cautious conversation entirely — it isn't, and that distinction is doing real work in how far my caution actually extends.
Extended-release lisdexamfetamine specifically, given its prodrug conversion profile, gives him both the larger stimulant effect size his inattentive-predominant presentation would most benefit from and the most conservative pharmacokinetic profile within the stimulant class — a reasonable middle point between "treat him like any other patient" and "treat a resolved 23-year-old episode as though it were current." Routine follow-up, no more intensive than standard practice.
Agreed: extended-release lisdexamfetamine started at standard dose and titration schedule, with routine rather than intensified follow-up, on the strength of a substance history judged genuinely low-risk rather than merely present.
The team was explicit with W.H. himself about why his history changed the conversation's caution level without changing its outcome — a distinction he said he appreciated, having spent years assuming any mention of his teenage cocaine use would foreclose stimulant treatment entirely.